the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Published 7 months ago • 89 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
1:33
prognostic impact of wt1 mutations in newly diagnosed and r/r aml
-
1:44
the genomics of rt and prognostic implications of rt characterization
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
6:07
novel prognostic index for pediatric all
-
2:08
real-world analysis of the most study: factors impacting progression to mf in patients with et
-
1:21
the prognostic impact of secondary-type mutations in patients with favorable risk aml
-
3:49
the patient burden of illness and unmet needs in scd & highlights from eha 2024
-
2:19
first-in-human phase i trial of at101, a novel anti-cd19 car-t, in r/r nhl
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
4:12
insight-mm: real-world patterns of patient characteristics
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
2:12
results from a phase i trial of tinostamustine in patients with r/r classical hl
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
6:28
outcomes following first-line therapy in routine clinical practice in alcl
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
5:16
the evolution of al amyloidosis therapy
-
3:31
a summary of the prognostic factors that can influence the outcomes of anti-cd19 car-t in r/r dlbcl
-
3:16
improving upon the standard of care for patients with richter’s transformation
-
2:04
state-of-the-art treatment for hr-mds
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
2:16
current and future treatment approaches for hr-mds